Supplemental Newborn Screening by MS/MS-Based Second-Tier Testing

Costs of False-Positive NBS Results

July 2008

Coming back to our example for screening for congenital adrenal hyperplasia in Minnesota, if we look at the 2007 data and look at it with the second-tier test that was actually implemented, with the second-tier test, the false-positive results were not 710, but only 41. The false-positive rate was only 0.06% as opposed to almost 1%.  The cost of clinical follow-up was reduced to $38,000; however, one has to pay for the second-tier test. Overall, the total follow-up cost is not $600,000, but $62,000 with a savings of 89%.

< Previous Slide

Costs of False-Positive Results

Next Slide >

 

Jump to section:

• Introduction
• What is Newborn Screening?
• Evolution of Newborn Screening
• ACMG* Uniform Panel
• MS/MS Impact on Newborn Screening
• Newborn Screening Performance in the USA (MS/MS)
• Costs of False-Positive NBS Results
• Newborn Screening in Minnesota
• MN Newborn Screening Program
• Costs of False-Positive NBS Results
• What is Second-Tier Testing?
• Second-Tier Testing is Performed for the Following "Problem" Analytes
• Why Second-Tier Testing?
• Costs of False-Positive NBS Results
• Impact of Second-Tier Testing on Performance of Newborn Screening by MS/MS at Mayo Clinic
• Questions?